Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways

被引：892
|
作者：
Fearon, Kenneth C. H. [1 ]
Glass, David J. [2 ]
Guttridge, Denis C. [3 ]
机构：
[1] Univ Edinburgh, Royal Infirm, Sch Clin Sci & Community Hlth, Edinburgh EH16 4SA, Midlothian, Scotland
[2] Novartis Inst Biomed Res, Cambridge, MA 02139 USA
[3] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA
来源：
CELL METABOLISM | 2012年 / 16卷 / 02期
关键词：
SKELETAL-MUSCLE ATROPHY; TUMOR-NECROSIS-FACTOR; ACUTE-PHASE RESPONSE; UBIQUITIN LIGASE ATROGIN1/MAFBX; ADIPOSE TRIGLYCERIDE LIPASE; PROTEOLYSIS INDUCING FACTOR; FOXO TRANSCRIPTION FACTORS; SYNTHASE KINASE 3-BETA; MESSENGER-RNA LEVELS; KAPPA-B ACTIVATION;
D O I：
10.1016/j.cmet.2012.06.011
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Cancer cachexia is characterized by a significant reduction in body weight resulting predominantly from loss of adipose tissue and skeletal muscle. Cachexia causes reduced cancer treatment tolerance and reduced quality and length of life, and remains an unmet medical need. Therapeutic progress has been impeded, in part, by the marked heterogeneity of mediators, signaling, and metabolic pathways both within and between model systems and the clinical syndrome. Recent progress in understanding conserved, molecular mechanisms of skeletal muscle atrophy/hypertrophy has provided a downstream platform for circumventing the variations and redundancy in upstream mediators and may ultimately translate into new targeted therapies.
引用
收藏
页码：153 / 166
页数：14
相关论文
共 50 条
  • [1] Metabolic Changes During Cancer Cachexia Pathogenesis
    Shyh-Chang, Ng
    TRANSLATIONAL RESEARCH IN BREAST CANCER: BIOMARKER DIAGNOSIS, TARGETED THERAPIES AND APPROACHES TO PRECISION MEDICINE, 2017, 1026 : 233 - 249
  • [2] Mechanisms of metabolic dysfunction in cancer-associated cachexia
    Petruzzelli, Michele
    Wagner, Erwin F.
    GENES & DEVELOPMENT, 2016, 30 (05) : 489 - 501
  • [3] Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment
    Miyamoto, Yuji
    Hanna, Diana L.
    Zhang, Wu
    Baba, Hideo
    Lenz, Heinz-Josef
    CLINICAL CANCER RESEARCH, 2016, 22 (16) : 3999 - 4004
  • [4] Mechanisms of Cancer Cachexia
    Tisdale, Michael J.
    PHYSIOLOGICAL REVIEWS, 2009, 89 (02) : 381 - 410
  • [5] Transforming Growth Factor-Beta Signaling in Cancer-Induced Cachexia: From Molecular Pathways to the Clinics
    Balsano, Rita
    Kruize, Zita
    Lunardi, Martina
    Comandatore, Annalisa
    Barone, Mara
    Cavazzoni, Andrea
    Cecconi, Andrea David Re
    Morelli, Luca
    Wilmink, Hanneke
    Tiseo, Marcello
    Garajova, Ingrid
    van Zuylen, Lia
    Giovannetti, Elisa
    Piccirillo, Rosanna
    CELLS, 2022, 11 (17)
  • [6] Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions
    Siddiqui, Jawed A.
    Pothuraju, Ramesh
    Jain, Maneesh
    Batra, Surinder K.
    Nasser, Mohd W.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2020, 1873 (02):
  • [7] Cancer cachexia: multilevel metabolic dysfunction
    Berriel Diaz, Mauricio
    Rohm, Maria
    Herzig, Stephan
    NATURE METABOLISM, 2024, : 2222 - 2245
  • [8] Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia can findings from animal models be translated to humans?
    Mueller, Tara C.
    Bachmann, Jeannine
    Prokopchuk, Olga
    Friess, Helmut
    Martignoni, Marc E.
    BMC CANCER, 2016, 16
  • [9] The Role of Inflammatory Pathways in Cancer-Associated Cachexia and Radiation Resistance
    Laine, Aaron
    Iyengar, Puneeth
    Pandita, Tej K.
    MOLECULAR CANCER RESEARCH, 2013, 11 (09) : 967 - 972
  • [10] TNF-α and cancer cachexia: Molecular insights and clinical implications
    Patel, Hetal J.
    Patel, Bhoomika M.
    LIFE SCIENCES, 2017, 170 : 56 - 63
12345